Jocelynn Dantis

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas

Fábio M. Iwamoto, Andreas F. Hottinger, Sasan Karimi et al. · Neuro-Oncology · 2011 · 92 citations · Full text

Medicine, Oncology, Surgery +17

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era

Christine Carico, Miriam Nuño, Debraj Mukherjee et al. · PLoS ONE · 2012 · 72 citations · Full text

Medicine, Cancer Biology, Oncology +17

YKL‐40 and MMP‐9 as serum markers for patients with primary central nervous system lymphoma

Andreas F. Hottinger, Fábio M. Iwamoto, Sasan Karimi et al. · Annals of Neurology · 2011 · 38 citations · Full text

Medicine, Neurology, Oncology +14

High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era

Chirag G. Patil, Miriam Nuño, Adam Elramsisy et al. · Neuro-Oncology · 2012 · 29 citations · Full text

Medicine, Cancer Biology, Oncology +17

Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas

Fábio M. Iwamoto, Andreas F. Hottinger, Sasan Karimi et al. · Journal of Neuro-Oncology · 2011 · 25 citations · Full text

Medicine, Cancer Biology, Oncology +13